An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

(2018) Andrew M. Blumenfeld et al.   JOURNAL OF HEADACHE AND PAIN

Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data

(2017) Brendan Davies et al.   JOURNAL OF HEADACHE AND PAIN

Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting

(2017) Antonio Santoro et al.   NEUROLOGICAL SCIENCES

Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy

(2017) Simona Guerzoni et al.   Frontiers in Neurology

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

(2016) David W. Dodick et al.   HEADACHE

Onabotulinumtoxin-A treatment in Greek patients with chronic migraine

(2016) Michail Vikelis et al.   JOURNAL OF HEADACHE AND PAIN

Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting

(2016) Katja Kollewe et al.   JOURNAL OF NEURAL TRANSMISSION

Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study

(2016) Dawn C. Buse et al.   MAYO CLINIC PROCEEDINGS

Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine

(2015) Andrew M. Blumenfeld et al.   BMC Neurology

Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine

(2015) Kasra Maasumi et al.   HEADACHE

A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience

(2015) Andrea Negro et al.   JOURNAL OF HEADACHE AND PAIN

Best Practices for Patients With Chronic Migraine

(2015) Amaal J. Starling et al.   MAYO CLINIC PROCEEDINGS

OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study

(2015) Andrea Negro et al.   SpringerPlus

OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm

(2015) María Isabel Pedraza et al.   SpringerPlus

Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?

(2014) Eva Cernuda-Morollón et al.   CEPHALALGIA

Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

(2014) Modar Khalil et al.   JOURNAL OF HEADACHE AND PAIN

A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study

(2013) Lars J Stovner et al.   CEPHALALGIA

Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)

(2012) L. M. Bloudek et al.   JOURNAL OF HEADACHE AND PAIN

Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review

(2011) Michel Lantéri-Minet et al.   CEPHALALGIA

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program

(2011) Sheena K. Aurora et al.   HEADACHE

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

(2010) SK Aurora et al.   CEPHALALGIA

Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)

(2010) AM Blumenfeld et al.   CEPHALALGIA

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

(2010) HC Diener et al.   CEPHALALGIA

Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program

(2010) Andrew Blumenfeld et al.   HEADACHE

Employment and Work Impact of Chronic Migraine and Episodic Migraine

(2010) Walter F. Stewart et al.   JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE

Global prevalence of chronic migraine: A systematic review

(2009) JL Natoli et al.   CEPHALALGIA

Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment

(2008) M. E. Bigal et al.   NEUROLOGY